Datapoint: FDA Approves Bristol Myers Squibb’s Breyanzi

After a series of regulatory and manufacturing delays, the FDA last week approved Bristol Myers Squibb’s CAR-T drug Breyanzi for the treatment of large B-cell lymphoma in patients who have not responded to or relapsed following other systemic treatments. Two other CAR-T therapies, Novartis’s Kymriah and Gilead’s Yescarta, are approved for the treatment of large B-cell lymphoma. Under the pharmacy benefit, Kymriah and Yescarta both hold preferred status for 9% of all covered lives.

SOURCE: MMIT Analytics, as of 2/8/21

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
November 24

Datapoint: Keytruda Scores Major Kidney Cancer Nod

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
November 23

Datapoint: Zing Health Acquires Lasso Healthcare

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
November 22

Datapoint: Paramount Loses Ohio Medicaid Battle

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today